

Cipla tops BW India's Most Sustainable Companies Rankings for 2022-23

Mumbai, India; June 30 2023: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has been ranked 1st in the Pharmaceuticals & Healthcare Sector and 5th in the Top 50 Most Sustainable Companies at the 3rd edition of BW India's Most Sustainable Companies Awards 2022-23. This recognition acknowledges Cipla's efforts in the areas of Environment Social and Governance, encompassing all three pillars of sustainability.

Commenting on this achievement, **Geena Malhotra, Global Chief Technology Officer** said, "At Cipla we recognise the synergy between purpose and passion, benefitting both people and the planet. This recognition is a testament to our dedication towards creating social impact for communities and serving markets to promote healthier people and a healthier planet through active environmental stewardship."

Cipla has a robust governance model focused on sustainability, with a dedicated Sustainability Council overseeing the implementation of a roadmap, monitoring, and reporting of sustainability initiatives across the company. The company is actively working towards important ESG goals, such as achieving water and carbon neutrality, zero waste to landfill, and prioritizing the well-being of employees and partners in its manufacturing operations. In line with its supply chain sustainability, Cipla has implemented a sustainable supply chain policy and code of conduct for suppliers, emphasizing the need for adherence to environmental and social standards. Furthermore, the company is exploring innovative approaches to potentially minimize or eliminate the need for costly animal or human bio studies.

The BW recognition further enhances Cipla's existing recognition for its industry leading ESG endeavours. The company has been ranked among the top 30 companies in the Indian Corporate Governance Scorecard 2021 and selected in the Dow Jones Sustainability Emerging Markets Index. Cipla was also acknowledged as a "Challenger in Mega Large Business Pharma Sector" at the Frost & Sullivan and TERI's Sustainability 4.0 Award 2022 and included in the S&P global sustainability yearbook for 2023. Additionally, the company is a constituent of the MSCI All Country World Index and has an ESG Rating of BBB.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ countries. Cipla is the 3rd largest in pharma in India (IQVIA MAT May'23), 3rd largest in the pharma private market in South Africa (IQVIA MAT May'23), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A

responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.

For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Media Contacts:**Corporate Communications**

Heena Kanal

E-Mail: Heena.kanal@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com